Analyst firms · Wedbush · ZNTL

Wedbush ZNTL price target and rating history

Zentalis Pharmaceuticals Inc. (ZNTL) · Health Care

Wedbush rates Zentalis Pharmaceuticals Inc. (ZNTL) Outperform with a $6 price target, as of its latest action on Nov 10, 2026. It has published 4 rating actions on ZNTL since November 2023, including 2 upgrades and 2 downgrades. Across 5 firms with a ZNTL price target in the last 12 months, the median target is $8. Wedbush's $6 is 25% below that.

Current rating
Outperform
Price target
$6
Median target, all firms
$8
Actions on ZNTL
4

Wedbush price target on ZNTL

$12$8$4202420252026
Wedbush price target on ZNTL, each point a stated target, November 2023 to November 2026.

Every Wedbush rating on ZNTL

How other firms rate ZNTL

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
WedbushOutperform$6Nov 10, 2026
Leerink PartnersOutperform$8Oct 5, 2026
Wells FargoEqual Weight$5Sep 30, 2026
William BlairOutperformSep 16, 2026
Rodman & RenshawBuy$11Jul 23, 2026
MizuhoOutperform$8Jul 17, 2026

Questions about Wedbush and ZNTL

What is Wedbush's price target for ZNTL?
Wedbush's latest stated price target for Zentalis Pharmaceuticals Inc. (ZNTL) is $6, from its action on Nov 10, 2026.
What is Wedbush's rating on ZNTL?
Wedbush rates ZNTL Outperform, a bullish rating, as of Nov 10, 2026.
When did Wedbush last change its view on ZNTL?
On Nov 10, 2026, Wedbush upgrades to Outperform from Neutral, price target $6.
How does Wedbush's ZNTL target compare with other analysts?
Across 5 firms with a ZNTL price target in the last 12 months, the median target is $8. Wedbush's $6 is 25% below that.

More ZNTL rating histories

All Wedbush ratingsZNTL news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.